Recently, Wondfo Biotech announced that several of its in vitro diagnostic (IVD) products have successfully obtained Medical Device Registration Certificates from China’s National Medical Products Administration (NMPA). The newly approved products span multiple clinical areas, including infectious disease testing, inflammatory markers, and cardiac biomarkers, significantly expanding the company’s point-of-care testing (POCT) portfolio. Notable among them are multiplex assays for rapid detection of pathogens such as influenza virus and respiratory syncytial virus (RSV), as well as high-sensitivity cardiac troponin I (hs-cTnI) for early diagnosis of cardiovascular diseases. These approvals underscore Wondfo’s strong capabilities in R&D innovation and quality control, providing a solid foundation for both domestic and international market expansion. As a leading POCT provider in China, Wondfo continues to invest heavily in research and development to advance its technological platforms and deliver efficient, accurate, and user-friendly diagnostic solutions globally. The recent regulatory milestones mark a significant step forward in the company’s strategy of product diversification and global growth, enhancing its competitiveness in the international IVD market.
近日，万孚生物宣布其多款体外诊断产品成功获得国家药品监督管理局（NMPA）颁发的医疗器械注册证。此次获批的产品涵盖传染病检测、炎症标志物、心肌标志物等多个临床应用领域，进一步丰富了公司在即时检测（POCT）平台上的产品线。其中，包括用于快速筛查流感病毒、呼吸道合胞病毒等病原体的多重联检试剂，以及高敏肌钙蛋白I（hs-cTnI）等心血管疾病早期诊断指标。这些新产品的获批不仅体现了万孚生物在研发创新和质量控制方面的综合实力，也为其拓展国内外市场提供了有力支撑。作为国内领先的POCT企业，万孚生物持续加大研发投入，推动产品技术升级，致力于为全球医疗机构提供高效、精准、便捷的诊断解决方案。此次多项注册证的取得，标志着公司在多元化布局和国际化战略方面迈出了坚实一步，有望进一步提升其在全球体外诊断市场的竞争力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/4782.html